- Home
- HYPR vs BDTX Comparison
HYPR vs BDTX Comparison
Compare HYPR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | BDTX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.5M | 116.8M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HYPR | BDTX |
|---|---|---|
| Price | $1.17 | $2.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $1.45 | ★ $10.20 |
| AVG Volume (30 Days) | 495.1K | ★ 588.6K |
| Earning Date | 03-18-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.21 | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | ★ $13,563,000.00 | N/A |
| Revenue This Year | $35.37 | N/A |
| Revenue Next Year | $18.33 | N/A |
| P/E Ratio | ★ N/A | $5.51 |
| Revenue Growth | ★ 5.22 | N/A |
| 52 Week Low | $0.53 | $1.20 |
| 52 Week High | $2.22 | $4.94 |
Technical Indicators
Market Signals| Indicator | HYPR | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 44.03 |
| Support Level | $1.04 | $1.93 |
| Resistance Level | $1.18 | $2.30 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 27.94 | 48.89 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.